Bio Medica Laboratories IPO Listing 2026 – Allotment, Demat Credit & BSE SME Debut

The Bio Medica Laboratories IPO has been listed on the NSE (National Stock Exchange) at a discount of 20%, with the listing price recorded at ₹111.20 per share. The IPO’s Grey Market Premium (GMP) was last noted at ₹0, indicating weak or neutral sentiment in the unofficial market ahead of listing.

On the subscription side, the IPO received a total subscription of 2.26 times by the final day. The retail portion was subscribed 2.92 times, showing decent participation from individual investors, while the NII segment subscribed 1.30 times. The strongest demand came from QIB investors at 15.94 times, reflecting significant institutional interest despite the overall listing resulting in a discount.

Image Reference : https://www.nseindia.com/

Bio Medica Laboratories IPO Listing Details

About Company

BIO MEDICA LABORATORIES LIMITED is a leading parenteral manufacturing company based in Central India, known for its strong focus on quality, innovation, and healthcare excellence. The company specializes in producing a wide range of parenteral formulations, including injectables for human and veterinary applications. Built on a foundation of Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP), BIO MEDICA ensures that every product meets strict international standards of safety, purity, and effectiveness. Its modern manufacturing facilities are equipped with advanced technology, enabling consistent production of high-quality injectable solutions for domestic as well as global markets.

The company offers a diverse portfolio of injectable products designed to meet the needs of hospitals, healthcare providers, and veterinary care sectors. With a growing export presence, BIO MEDICA LABORATORIES LIMITED continues to expand its global footprint by delivering reliable healthcare solutions worldwide. The organization is driven by a strong mission to improve health and well-being through innovative parenteral formulations for both humans and animals. Its vision is to become a globally recognized leader in the pharmaceutical manufacturing industry by maintaining excellence, sustainability, and continuous improvement in all aspects of its operations.